# US 10,307,401 B2 · Compositions and methods for treatment of prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,401 B2
- Document ID: US10307401B2
- Status: Granted
- Kind: B2
- Application number: 15/688,785
- Filed: 2017-08-28
- Published: 2018-03-08
- Granted: 2019-06-04
- Earliest claimed: 2016-08-29
- Assignees: California Institute of Technology
- Applicants: California Institute of Technology
- Inventors: Peter B. Dervan; Nickolas G. Nickols; Fei Yang; Alexis A. Kurmis
- Web page: https://patentgrep.com/patent/US10307401B2

## CPC

- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 5/28: Antiandrogens
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions and methods for the treatment of prostate cancer. The present invention relates to polyamides and prostate agents, for example, to inhibit an androgen receptor signaling axis, and the use of these compositions in the treatment of prostate cancer.

## Claims

### Claim 1

A combination drug that inhibits the growth of a prostate cancer cell, wherein the combination drug comprises a polyamide and a prostate agent, wherein the polyamide has structure 61 as follows:
and wherein the prostate agent is enzalutamide.

### Claim 2 (depends on 1)

The combination drug of claim 1, wherein said combination drug further comprises a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The combination drug of claim 1, wherein said combination drug is formulated for parenteral administration.

### Claim 4 (depends on 1)

The combination drug of claim 1, wherein the combination drug is formulated for subcutaneous administration.

### Claim 5 (depends on 1)

The combination drug of claim 1, wherein the polyamide and the prostate agent comprise a single formulation.

### Claim 6 (depends on 1)

The combination drug of claim 1, wherein the polyamide and the prostate agent comprise a single dosage.

### Claim 7 (depends on 1)

The combination drug of claim 1, wherein the polyamide and the prostate agent are prepared as one preparation.

### Claim 8 (depends on 1)

The combination drug of claim 1, wherein the polyamide and the prostate agent are prepared as two preparations.

### Claim 9 (depends on 8)

The combination drug of claim 8, wherein the polyamide and the prostate agent are prepared as two preparations and wherein one preparation comprises the polyamide and the other preparation comprises the prostate agent.